Topical 3-bromopyruvate is a novel targeted therapy for melanoma in a preclinical model.
J Dermatol Sci
; 92(2): 134-142, 2018 Nov.
Article
en En
| MEDLINE
| ID: mdl-30206027
ABSTRACT
BACKGROUND:
Targeting cancer metabolism is a promising strategy in improving cancer treatment.OBJECTIVE:
To introduce a targeted therapy with topical 3-bromopyruvate (3BP), aglycolytic inhibitor, into the clinic in the near future.METHOD:
We investigated the anti-tumor efficacy of 3BP on melanoma cells in vitro and in a preclinical model.RESULTS:
Our cell-based study demonstrated that 3BP showed cytotoxicity for melanoma cells under anchorage-dependent or independent cell growth via a reactive oxygen species-mediated and caspase-independent cell death pathway. Moreover, 3BP inhibited both self-renewal potential and growth of slow-cycling phenotype in melanoma cells. Remarkably, the preclinical mouse xenograft model shed light on topical application of 3BP, showing significant anti-tumor effects with no apparent toxicity in surrounding normal tissues.CONCLUSION:
We have now proposed that a targeted therapy with topical 3BP is an innovative strategy for adjuvant chemotherapy of technically or medically unresectable melanoma and possibly other skin cancers.Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Piruvatos
/
Neoplasias Cutáneas
/
Melanoma Experimental
/
Inhibidores Enzimáticos
Idioma:
En
Revista:
J Dermatol Sci
Año:
2018
Tipo del documento:
Article
País de afiliación:
Japón